CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Highlights Charles River Laboratories International, Inc.

Stocks

CRL

US1598641074

Biotechnology & Medical Research

Market Closed - NYSE 16:00:02 2026-10-13 EDT			5-day change	1st Jan Change
299.02 ^USD	-0.94%		-3.78%	+49.90%

10-13	Magellan Stem Cells Collaborates with Charles River Laboratories International, Inc. to Advance Stem Cell and Regenerative Medicine Development	CI
10-13	Charles River Laboratories Working With Magellan Stem Cells to Test Osteoarthritis Therapy	MT

Highlights

10-13	Magellan Stem Cells Collaborates with Charles River Laboratories International, Inc. to Advance Stem Cell and Regenerative Medicine Development	CI
10-13	Charles River Laboratories Working With Magellan Stem Cells to Test Osteoarthritis Therapy	MT
10-06	Charles River Laboratories International, Inc. and Autolomous Launch Apollo Orchestrate Within Charles River's Apollo Platform	CI
09-24	Charles River Laboratories Reaffirms Fiscal 2026 Guidance; Issues 2030 Growth Projections	MT
09-24	(CRL) Charles River Laboratories Expects 2026 Adjusted EPS at Upper End of $11.15 - $11.45, vs. FactSet Est of $11.33	MT
09-17	Charles River Laboratories International Introduces Rapid Cell Banking Programs with Next-Generation Sequencing Characterization	CI
09-16	Charles River Laboratories to Provide Update on New Approach Methodologies Strategy on Investor Day, RBC Says	MT
09-08	Charles River Laboratories International Implements Endosafe Cartridge Technology Automated Manufacturing Suite	CI
08-20	Charles River, Medigen Partner on Multivalent Enterovirus Vaccine	MT
08-05	Top Midday Gainers	MT
08-05	Tranche Update on Charles River Laboratories International, Inc.'s Equity Buyback Plan announced on November 5, 2025.	CI
08-05	Charles River Laboratories International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 27, 2026	CI
08-05	Charles River Laboratories Fiscal Q2 Non-GAAP Earnings, Revenue Fall; Lifts 2026 Guidance	MT
08-05	Charles River Laboratories International, Inc. Updates Earnings Guidance for 2026	CI
08-05	(CRL) Charles River Laboratories Expects 2026 Adjusted EPS Range $11.15 - $11.45, vs. FactSet Est of $11.11	MT
08-05	Earnings Flash (CRL) Charles River Laboratories Posts Fiscal Q2 Revenue $1.00B, vs. FactSet Est of $977.2M	MT
08-05	Earnings Flash (CRL) Charles River Laboratories Posts Fiscal Q2 Adjusted EPS $3.02, vs. FactSet Est of $2.74	MT
08-05	Charles River lifts profit forecast on improving biotech demand	RE
07-13	Charles River Laboratories to Provide Cell Sequencing Services to Arovella Therapeutics	MT
07-13	Charles River Provides Ngs Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches	CI
05-13	Charles River Laboratories, Medipost Sign MoU on GMP-Compliant Testing	MT
05-11	Charles River Laboratories International, Inc. Approves Ratification of PricewaterhouseCoopers LLP as Independent Auditors	CI
05-11	Charles River Laboratories International, Inc. Accelerates Digital Pathology with Ai-Powered End-To-End Workflow	CI
05-08	Charles River Laboratories International, Inc. Seeks M&A Opportunities	CI
05-07	Tranche Update on Charles River Laboratories International, Inc.'s Equity Buyback Plan announced on November 5, 2025.	CI